Sashidhar Manthravadi, MD
Hematology & Oncology · Liberty, MONPI 1629495502
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,066 of the $2,666 with a category attached, or 77.5%. It is spread thinly across 35 manufacturers, the largest accounting for just 8.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,743 and has fallen 97.1% since, to $51 in 2024.
Across 136 payments — averaging $19.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$221
- Bristol Myers Squibb$204
- E.r. Squibb & Sons, L.L.C.$198
- Genentech USA, Inc.$161
- Gilead$152
- Seagen Inc.$143
- plus $2K from 29 others
What the payments were for
- Food & beverage$2,06677%
- Education$60023%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 14 | $221 |
| Bristol Myers Squibb | 12 | $204 |
| E.r. Squibb & Sons, L.L.C. | 14 | $198 |
| Genentech USA, Inc. | 10 | $161 |
| Gilead(2 entities) | 9 | $152 |
| Seagen Inc. | 3 | $143 |
| AbbVie | 4 | $136 |
| AstraZeneca | 7 | $133 |
| Amgen | 7 | $128 |
| AVEO Pharmaceuticals, Inc. | 2 | $112 |
| Eisai Inc. | 6 | $110 |
| Pfizer | 6 | $96 |
| Daiichi Sankyo Inc. | 5 | $91 |
| Incyte Corporation | 1 | $87 |
| GSK | 5 | $81 |
| Merck | 4 | $66 |
| Sanofi | 3 | $62 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $61 |
| Karyopharm Therapeutics Inc. | 1 | $48 |
| Beigene USA, Inc. | 3 | $44 |
| Kyowa Kirin, Inc. | 2 | $41 |
| Array Biopharma Inc | 2 | $40 |
| Foundation Medicine, Inc. | 1 | $32 |
| Regeneron Healthcare Solutions, Inc. | 1 | $28 |
| Tactile Systems Technology Inc | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $20 |
| Tolmar Pharmaceuticals, Inc. | 1 | $19 |
| Bayer | 1 | $19 |
| Exelixis Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $17 |
| Clovis Oncology, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Blueprint Medicines Corporation | 1 | $13 |
| Taiho Oncology, Inc. | 1 | $13 |
How this compares
$2,666 in reported general payments places this provider in the 55th percentile of 211 hematology & oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 17 | $482,962 |
| RevlimidLenalidomide | 12 | $335,231 |
| XtandiEnzalutamide | 23 | $330,154 |
| CalquenceAcalabrutinib Maleate | 16 | $245,971 |
| IbrancePalbociclib | 13 | $204,326 |
| BrukinsaZanubrutinib | 13 | $199,185 |
| VenclextaVenetoclax | 15 | $141,819 |
| Pazopanib Hcl | 11 | $70,264 |
| Abiraterone Acetate | 32 | $63,378 |
| EliquisApixaban | 53 | $36,453 |
| Anastrozole | 199 | $4,055 |
| Minocycline Hcl | 21 | $1,667 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 42 | $1,341 |
| Ondansetron Hcl | 104 | $1,299 |
| Letrozole | 41 | $959 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $198 | $482,96217 claims |
| Bristol Myers SquibbRevlimid | $204 | $335,23112 claims |
| Astellas Pharma US IncXtandi | $20 | $330,15423 claims |
| AstraZenecaCalquence | $133 | $245,97116 claims |
| PfizerIbrance, Eliquis | $96 | $240,77966 claims |
| Beigene USA, Inc.Brukinsa | $44 | $199,18513 claims |
| AbbVieVenclexta | $136 | $141,81915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 211 hematology & oncology providers in Missouri.
Other hematology & oncology in Liberty
- David SchlossmanColumbia$1.2M
- Mark FeslerSaint Louis$870K
- Kelly PendergrassLees Summit$189K
- Jonathan MizrahiSaint Louis$188K
- Shahzad RazaKansas City$123K
- Stephanie GraffKansas City$105K
- Muhammad MirzaWashington$65K
- Yifan TuSt. Louis$64K
- Whitney HensingKansas City$62K
- Shadi HaddadinJefferson City$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.